Doseology Announces $2M Financing to Accelerate Commercialization of Oral Stimulant Pouch Platform

Rhea-AI Summary

Doseology (OTCQB: DOSEF) arranged a non-brokered private placement to raise up to $2.0M by issuing up to 3,225,806 Units at $0.62 per Unit. Each Unit includes one share and one two-year warrant exercisable at $1.00, subject to acceleration.

The company said net proceeds will fund commercialization of its oral stimulant pouch platform: production equipment, pilot manufacturing facility, initial runs, inventory, marketing, distribution expansion and general working capital. Closing is subject to CSE approval and securities hold/resale restrictions.

Positive

• Financing secured for commercialization: $2.0M
• Clear use of proceeds for production, inventory and marketing
• Warrants provide potential follow-on capital at $1.00 exercise price

Negative

• Potential dilution: up to 3,225,806 new shares from Units
• Resale restrictions and statutory hold reduce near-term liquidity
• Warrant acceleration may force earlier exercise or expiration

KELOWNA, BC, March 30, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD |OTCQB: DOSEF | FSE: VU70) ("Doseology" or the "Company") a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that it has arranged a non-brokered private placement of up to 3,225,806 units (each, a "Unit") at a price of $0.62 per Unit to raise aggregate gross proceeds of up to $2,000,000 (the "Offering").

Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one Share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder to acquire one additional Share at a price of $1.00 per Share for a period of two (2) years from the date of issuance, subject to acceleration. If the daily volume weighted  average  trading  price  of  the  Shares  on  the  Canadian Securities Exchange (the "CSE") (or such other exchange on which the Shares may become traded) for  any  period  of  20  consecutive  trading  days  equals  or  exceeds $2.00, at any time following the date that is four (4) months and one (1) day after the closing of the Offering, the Company may, upon providing written notice to the holders of the Warrants (the "Acceleration Notice"), accelerate the expiry date of the Warrants to the date that is 30 days following the date of the Acceleration Notice. If the Warrants are not exercised by the accelerated expiry date, the Warrants will expire and be of no further force or effect.

All securities issued pursuant to the Offering will be subject to a statutory hold period of four (4) months and one (1) day from the date of issuance. In addition, the securities issued pursuant to the Offering will be subject to the following contractual resale restrictions: (i) one-third (1/3) may be sold on the date that is four (4) months and one (1) day from closing of the Offering, (ii) one-third (1/3) may be sold on the date that is eight (8) months from closing of the Offering, and (iii) the remaining one-third (1/3) may be sold on the date that is twelve (12) months from closing of the Offering.

The Company may pay finders' fees to eligible finders in accordance with applicable securities laws and the policies of the CSE. Closing of the Offering remains subject to customary closing conditions, including approval of the CSE.

The Company intends to use the net proceeds of the Offering to advance its commercialization strategy for oral pouch products, including production equipment, pilot manufacturing facility development, initial production runs, inventory build, marketing and distribution expansion, and general working capital.

"This financing positions Doseology to advance its commercialization strategy and scale production capabilities," said Larry Latowsky, Executive Chairman of the Company. "We are focused on building a scalable platform within the emerging oral pouch category."

About Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70)

Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.

From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.

For more information visit:

Corporate: www.doseology.com
Shop: www.feedthatbrain.com

On behalf of the Board of Directors,
Chris Jackson
CEO, Director
Doseology Sciences Inc.

Investor & Media Contact:
Email: hello@doseology.com
Phone: 604.908.3095

Forward Looking Statements

This news release contains "forward‑looking information" within the meaning of applicable Canadian securities laws ("FLI"). In this news release, FLI includes statements regarding, among other things: the completion and timing of the Offering; the receipt of required regulatory approvals, including approval of the CSE; the intended use of proceeds of the Offering; the Company's ability to advance its commercialization strategy for oral pouch products (including the acquisition of production equipment, development of a pilot manufacturing facility, initial production runs, inventory build, and marketing and distribution expansion); and the Company's business and growth plans relating to its oral pouch and functional stimulant product technologies.

FLI is based on management's current expectations, estimates, projections and assumptions as of the date hereof. Assumptions include, among other things: that the Company will be able to complete the Offering on the terms described (or at all); that the Company will satisfy customary closing conditions; that market conditions will remain conducive to the Offering; that suppliers, contractors and other third parties will perform as expected in connection with equipment procurement and facility development; and that the Company will be able to execute its commercialization plans and deploy the net proceeds as intended.

FLI is subject to known and unknown risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by FLI. These risks include, among other things: the risk that the Offering is not completed on the proposed terms or within the anticipated timeframe (or at all); the risk that required regulatory approvals, including approval of the CSE, are not obtained; changes in general economic, financial market and business conditions; supply chain disruptions and cost increases affecting equipment procurement, facility development, production and inventory; and other risks described in the Company's continuous disclosure filings available on SEDAR+ at https://www.sedarplus.ca.

Readers are cautioned not to place undue reliance on FLI. The Company does not undertake to update or revise any FLI, except as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this press release. 

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Logo - https://mma.prnewswire.com/media/2858641/5890069/Doseology_Sciences_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/doseology-announces-2m-financing-to-accelerate-commercialization-of-oral-stimulant-pouch-platform-302728474.html

SOURCE Doseology Sciences Inc.

FAQ

How much financing did Doseology (DOSEF) announce on March 30, 2026?

Doseology announced a non-brokered private placement to raise up to $2.0M. According to the company, proceeds will be raised by issuing up to 3,225,806 Units at $0.62 each, each Unit including one share and one warrant.

What are the terms of the warrants included in Doseology's (DOSEF) offering?

Each warrant allows purchase of one share at $1.00 for two years from issuance. According to the company, warrants are subject to 30-day acceleration if the 20-day VWAP exceeds $2.00 after the four-month hold period.

How will Doseology (DOSEF) use the net proceeds from the $2M placement?

The company will deploy proceeds to advance commercialization of oral pouch products and scale production. According to the company, uses include production equipment, pilot facility development, initial production runs, inventory, marketing, distribution expansion and working capital.

What resale and hold restrictions apply to securities from Doseology's (DOSEF) financing?

Securities issued are subject to a statutory four-month-and-one-day hold and staged contractual resale over 12 months. According to the company, one-third may be sold after four months plus one day, another third at eight months, and the remainder at twelve months.

Does the Doseology (DOSEF) offering require regulatory or exchange approval?

Closing is subject to customary conditions, including approval of the Canadian Securities Exchange. According to the company, the offering may also involve eligible finders who could receive fees in accordance with applicable securities laws and CSE policies.